Cadila Healthcare is currently trading at Rs. 439.45, up by 3.75 points or 0.86% from its previous closing of Rs. 435.70 on the BSE.
The scrip opened at Rs. 436.00 and has touched a high and low of Rs. 442.65 and Rs. 436.00 respectively. So far 5,586 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 460.00 on 17-Feb-2017 and a 52 week low of Rs. 305.00 on 12-Apr-2016.
Last one week high and low of the scrip stood at Rs. 444.25 and Rs. 407.25 respectively. The current market cap of the company is Rs. 45,060.00 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.18% and 8.03% respectively.
Cadila Healthcare, along with subsidiary Zydus Pharmaceuticals (USA) Inc, has finalized an agreement with Supernus Pharmaceuticals Inc to settle all outstanding patent litigation related to Trokendi XR (topiramate) extended-release capsules.
Under the terms of the pact, Supernus grants a license to market Zydus' generic version of Trokendi XR (topiramate) extended-release capsules beginning on January 1, 2023, or earlier, under certain circumstances. The drug is used for treatment of certain types of seizures.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.